Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleExperimental Studies

Gene Therapy Using Adenovirus Against Malignant Mesothelioma

AKINOBU GOTOH, TAKESHI KANNO, HISAO NAGAYA, TAKASHI NAKANO, CHIHARU TABATA, KAZUYA FUKUOKA, MASATOSHI TAGAWA and TOMOYUKI NISHIZAKI
Anticancer Research September 2012, 32 (9) 3743-3747;
AKINOBU GOTOH
1Laboratory of Cell and Gene Therapy Institute for Advanced Medical Sciences, Hyogo College of Medicine, Nishinomiya, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TAKESHI KANNO
2Division of Bioinformation, Department of Physiology, Hyogo College of Medicine, Nishinomiya, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HISAO NAGAYA
1Laboratory of Cell and Gene Therapy Institute for Advanced Medical Sciences, Hyogo College of Medicine, Nishinomiya, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TAKASHI NAKANO
3Division of Pulmonary Medicine, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan
4Cancer Center, Hyogo College of Medicine, Nishinomiya, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
CHIHARU TABATA
3Division of Pulmonary Medicine, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KAZUYA FUKUOKA
4Cancer Center, Hyogo College of Medicine, Nishinomiya, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MASATOSHI TAGAWA
5Division of Pathology and Cell Therapy, Chiba Cancer Center Research Institute, Chiba, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TOMOYUKI NISHIZAKI
2Division of Bioinformation, Department of Physiology, Hyogo College of Medicine, Nishinomiya, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: tomoyuki@hyo-med.ac.jp
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Background: Adenovirus vectors have been utilized for cancer gene therapies. The present study examined the oncolytic effects of adenovirus type 5 (Ad5) and fiber-substituted conditionally replicating adenovirus (CRAD) Ad5/F35 vectors on the human malignant mesothelioma cells MSTO-211H, NCI-H28, NCI-H2052, and NCI-H2452 cells. Materials and Method: For the adenovirus, the first mRNA/protein to be made (~1 h after infection) is E1A. Ad5F35 and Ad5 CRAD vectors containing the E1 gene controlled by the human midkine promoter (Ad5F35/MKp-E1 and Ad5/MKp-E1, respectively) were constructed. Western blotting and cell viability assays were carried out in cells transfected with Ad5/MKp-E1 and Ad5F35/MKp-E1. Results: Coxsackie and adenovirus receptor (CAR), a cell surface target of Ad5, and CD46, a cell surface target of Ad35, were expressed in all the malignant mesothelioma cell lines examined here, as much as in HEK293 cells, with no significant differences in the expression levels among cells. Both Ad5/MKp-E1 and Ad5F35/MKp-E1 induced oncolysis of malignant mesothelioma cells in a viral particle-dependent manner, with similar efficacy. Conclusion: The results of the present study suggest that both Ad5/MKp-E1 and Ad5F35/MKp-E1 are useful for the gene therapy of human malignant mesothelioma.

  • Adenovirus
  • oncolysis
  • CAR
  • CD46
  • malignant mesothelioma

Malignant mesothelioma is an aggressive and highly lethal tumor which is caused by occupational exposure to asbestos fibers, particularly of the amphibole type (1). In spite of great efforts, no promising treatment has been provided as yet for malignant mesothelioma. Establishing new effective therapies for malignant mesothelioma, therefore, is of great importance.

Recent studies have focused upon gene therapies using adenovirus vectors for a variety of cancer types (2). The critical key point for the gene therapies is the quantity of adenovirus, which is transferred into tumor cells through adenovirus-targeting receptors (3, 4). Another key point for gene therapy is to reduce side-effects. To address this point, conditionally replicating adenovirus (CRAD) has been developed (5, 6). CRAD is capable of inducing tumor-specific cell death and of amplifying oncolysis due to intratumoral replication (7). CRAD is also capable of inducing oncolysis of cancer cells neighboring primarily infected cells by secondary infection, to an extent greater than that for non-replicating adenoviruses (8-10).

For renal cell carcinoma (RCC), an adenovirus vector containing an Arg-Gly-Asp (RGD) motif has been shown to increase the efficacy of gene transfer into cells (11). Adenovirus type 5 (Ad5) has been widely used for gene therapies. Ad5 is infected into cells through coxsackie and adenovirus receptor (CAR) (12). CAR expression, however, is low in some types of cancer cell (13). In contrast, CD46, a cell surface receptor for adenovirus type 35 (Ad35), is more commonly expressed in cancer cells (14).

For the adenovirus, the first mRNA/protein to be made (~1 h after infection) is E1A. In the present study, we constructed a CRAD vector encoding the E1 gene under the control of a 0.6-kb midkine promoter without (Ad5/MKp-E1) and with replacement of the fiber knob for Ad5 by that for Ad35 (Ad5F35/MKp-E1), and examined their oncolytic effect on human malignant mesothelioma cells. We show here that both the Ad5/MKp-E1 and Ad5F35/MKp-E1 are suitable for gene therapy of human malignant mesothelioma.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Expression of CAR and CD46 protein. Western blotting for CAR (A) and CD46 (B) were carried out in cells, as indicated. The expression levels of each protein were normalized to those for β-actin. In the graphs, each column represents the mean (±SEM) expression of each protein (n=4 independent experiments).

Materials and Methods

Construction of CRAD vectors. Replication-competent adenovirus vector containing the E1 gene controlled by the midkine promoter was prepared as follows. The cytomegalovirus (CMV) promoter of pShuttle2 vector (Clontech Laboratories, Mountain View, CA, USA) was replaced with the 0.6-kb 5’-upstream regulatory region of the midkine gene and the pS-MK/E1 vector was produced by inserting the E1 gene downstream of the midkine region. To construct pAd5F35, the Ad5 fiber region on the pAdeno-X vector (Clontech Laboratories) was substituted with the Ad35 fiber region on the RHSP vector (Avior Therapeutics, Seattle, WA, USA). Ad5/MKp-E1 and Ad5F35/MKp-E1 were prepared by linking the pS-MK/E1 vector with pAdeno-X and pAd5F35, respectively.

Cell culture. Human malignant pleural mesothelioma cell lines MSTO-211H, NCI-H28, NCI-H2052 and NCI-H2452, and Met5A human mesothelial cells, were purchased from the American Type Culture Collection (Manassas, VA, USA) and HEK293 cells from RIKEN Bioresource Center (Tsukuba, Japan). Malignant mesothelioma and mesothelial cells were grown in RPMI-1640 medium and HEK293 cells in Dulbecco's modified Eagle's medium, supplemented with 10% heat-inactivated fetal bovine serum (FBS), 0.003% L-glutamine, penicillin (final concentration, 100 U/ml), and streptomycin (final concentration, 0.1 mg/ml), in a humidified atmosphere of 5% CO2 and 95% air at 37°C.

Western blotting. Western blotting was carried out by a method, as described previously (15). Briefly, cells were lysed with 1% (w/v) sodium dodecyl sulfate (SDS). Proteins were then separated by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) using a TGX gel (BioRad, Hercules, CA, USA) and then transferred to polyvinylidene difluoride membranes. Membranes were then blocked with TBS-T [150 mM NaCl, 0.1% (v/v) Tween20 and 20 mM Tris, pH 7.5] containing 5% (w/v) bovine serum albumin and subsequently incubated with antibodies against CAR (Santa Cruz Biotechnology, Santa Cruz, CA, USA), CD46 (Santa Cruz Biotechnology), and β-actin (Sigma, St Louis, MO, USA). Immunoreactivity was detected with an ECL kit (GE Healthcare, Piscataway, NJ, USA) and visualized using a chemiluminescence detection system (GE Healthcare). Protein concentrations for each sample were determined with a BCA protein assay kit (Pierce, Rockford, IL, USA). Signal intensities for CAR or CD46 protein were normalized by the intensity for β-actin.

Oncolysis assay. Cells (5×103) in 96-well plates were infected with Ad5/MKp-E1 or Ad5F35/MKp-E1 at 0.001-10000 viral particle (VP)/cells. Five days after infection, cells were incubated with Alamar Blue (Life Technologies, Gaithersburg, MD, USA) and the number of viable cells were counted by detecting the absorbance at 560 nm with a high-throughput microplate spectrophotometer (SpectraMax Plus 384; Molecular Devices, Sunnyvale, CA, USA). Viabilities for cells without infection with Ad5/MKp-E1 or Ad5F35/MKp-E1 were regarded as controls.

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

Oncolytic effects of Ad5/MKp-E1 and Ad5F35/MKp-E1. Cell viability was assayed 5 days after infection using an Alamar Blue in HEK293 (A), Met5A (B), MSTO-211H (C), NCI-H28 (D), NCI-H2052 (E), and NCI-H2452 cells (F). In the graphs, each point represents the mean (±SEM) percentage of basal levels (viabilities of cells uninfected) (n=6 independent experiments).

Results

Expression of CAR and CD46. As previously demonstrated (16), HEK293 cells abundantly express CAR and CD46 (Figure 1A and B). Met5A mesothelial cells and all the malignant mesothelioma cells examined here expressed CAR and CD46, to an extent similar to that of HEK293 cells (Figure 1A and B).

Oncolytic effects of Ad5/MKp-E1 and Ad5F35/MKp-E1. For HEK293 cells, Ad5/MKp-E1 and Ad5F35/MKp-E1 reduced cell viability in a VP-dependent manner, with Ad5F35/MKp-E1 efficacy being slightly higher than that of Ad5/MKp-E1 (Figure 2A). Ad5/MKp-E1 and Ad5F35/MKp-E1 also reduced cell viability in a VP-dependent manner for the Met5A mesothelial cells and all the malignant mesothelioma cells, with no difference in the efficacy between Ad5/MKp-E1 and Ad5F35/MKp-E1 (Figure 2B-F).

Discussion

Midkine is a heparin-binding growth factor that is induced by retinoic acid in embryonal carcinoma cells (17). It is implicated in mitogenesis, angiogenesis, anti-apoptosis, fibrinolysis, and transformation (18-22). Midkine is enriched in a variety of cancer cells originating from the esophagus, stomach, colon, liver, breast, and pancreas, while its expression in non-malignant cells is quite limited, with moderate expression in the kidney and weak expression in the lung, colon, and thyroid gland (23-27). The midkine promoter, accordingly, could be utilized for suicide gene therapy.

We, therefore, constructed Ad5 (Ad5/MKp-E1) and Ad5F35 CRAD vectors (Ad5F35/MKp-E1) encoding the E1 gene under the control of a 0.6-kb midkine promoter. Ad5 and Ad35 are infected into cells through CAR and CD46 (12, 14). CD46 is recognized to be more commonly expressed in cancer cells as compared with CAR (13). In the present study, however, CAR as well as CD46 were abundantly expressed in malignant mesothelioma cells. Both Ad5/MKp-E1 and Ad5F35/MKp-E1 exhibited sufficient oncolytic effect on all the malignant mesothelioma cell lines examined here, with no difference in the efficacy between Ad5/MKp-E1 and Ad5F35/MKp-E1. Ad5/MKp-E1 and Ad5F35/MKp-E1, thus, appear to be suitable for gene therapy of human malignant mesothelioma.

Conclusion

The results of the present study show that a sufficient and beneficial oncolytic effect on malignant mesothelioma cells is obtained with Ad5/MKp-E1 and Ad5F35/MKp-E1. These adenovirus vectors could be developed as a promising gene therapy option for malignant mesothelioma.

Footnotes

  • Potential Conflict of Interest Statement

    None of the Authors have any potential conflict of interest.

  • Received June 5, 2012.
  • Revision received July 27, 2012.
  • Accepted July 31, 2012.
  • Copyright© 2012 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved

References

  1. ↵
    1. Tsujimura T,
    2. Torii I,
    3. Sato A,
    4. Song M,
    5. Fukuoka K,
    6. Hasegawa S,
    7. Nakano T
    : Pathological and molecular biological approaches to early mesothelioma. Int J Clin Oncol 17: 40-47, 2012.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Guse K,
    2. Cerullo V,
    3. Hemminki A
    : Oncolytic Vaccinia virus for the treatment of cancer. Expert Opin Biol Ther 11: 595-608, 2011.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Bauerschmitz GJ,
    2. Barker SD,
    3. Hemminki A
    : Adenoviral gene therapy for cancer: From vectors to targeted and replication competent agents (review). Int J Oncol 21: 1161-1174, 2002.
    OpenUrlPubMed
  4. ↵
    1. Kanerva A,
    2. Hemminki A
    : Modified adenoviruses for cancer gene therapy. Int J Cancer 110: 475-480, 2004.
    OpenUrlCrossRefPubMed
  5. ↵
    1. Ganly I,
    2. Kirn D,
    3. Eckhardt G,
    4. Rodriguez GI,
    5. Soutar DS,
    6. Otto R,
    7. Robertson AG,
    8. Park O,
    9. Gulley ML,
    10. Heise C,
    11. Von Hoff DD,
    12. Kaye SB
    : A phase I study of Onyx-015, an E1B-attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin Cancer Res 6: 798-806, 2000.
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. Kirn D
    : Oncolytic virotherapy for cancer with the adenovirus dl1520 (Onyx-015): Results of phase I and II trials. Expert Opin Biol Ther 1: 525-538, 2001.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Biederer C,
    2. Ries S,
    3. Brandts CH,
    4. McCormick F
    : Replication-selective viruses for cancer therapy. J Mol Med (Berl) 80: 163-175, 2002.
    OpenUrlCrossRefPubMed
  8. ↵
    1. Alemany R,
    2. Balagué C,
    3. Curiel DT
    : Replicative adenoviruses for cancer therapy. Nat Biotechnol 18: 723-727, 2000.
    OpenUrlCrossRefPubMed
    1. Heise C,
    2. Kirn DH
    : Replication-selective adenoviruses as oncolytic agents. J Clin Invest 105: 847-851, 2000.
    OpenUrlPubMed
  9. ↵
    1. Ring CJ
    : Cytolytic viruses as potential anticancer agents. J Gen Virol 83: 491-502, 2002.
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Terao S,
    2. Acharya B,
    3. Suzuki T,
    4. Aoi T,
    5. Naoe M,
    6. Hamada K,
    7. Mizuguchi H,
    8. Gotoh A
    : Improved gene transfer into renal carcinoma cells using adenovirus vector containing RGD motif. Anticancer Res 29: 2997-3001, 2009.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Hamilton MM,
    2. Byrnes GA,
    3. Gall JG,
    4. Brough DE,
    5. King CR,
    6. Wei LL
    : Alternate serotype adenovector provides long-term therapeutic gene expression in the eye. Mol Vis 14: 2535-2546, 2008.
    OpenUrlPubMed
  12. ↵
    1. Okegawa T,
    2. Sayne JR,
    3. Nutahara K,
    4. Pong RC,
    5. Saboorian H,
    6. Kabbani W,
    7. Higashihara E,
    8. Hsieh JT
    : A histone deacetylase inhibitor enhances adenoviral infection of renal cancer cells. J Urol 177: 1148-1156, 2007.
    OpenUrlCrossRefPubMed
  13. ↵
    1. Gaggar A,
    2. Shayakhmetov DM,
    3. Lieber A
    : CD46 is a cellular receptor for group B adenoviruses. Nat Med 9: 1408-1412, 2003.
    OpenUrlCrossRefPubMed
  14. ↵
    1. Kamiya H,
    2. Kanno T,
    3. Fujita Y,
    4. Gotoh A,
    5. Nakano T,
    6. Nishizaki T
    : Apoptosis-related gene transcription in human A549 lung cancer cells via A3 adenosine receptor. Cell Physiol Biochem 29: 687-696, 2012.
    OpenUrlPubMed
  15. ↵
    1. Nagaya H,
    2. Tagawa M,
    3. Hiwasa K,
    4. Terao S,
    5. Kanno T,
    6. Nishizaki T,
    7. Gotoh A
    : Fiber-substituted conditionally replicating adenovirus for oncolysis of human renal carcinoma cells. Anticancer Res 32: 2985-2989, 2012.
    OpenUrlAbstract/FREE Full Text
  16. ↵
    1. Kadomatsu K
    : Midkine, a heparin-binding growth factor: Its discovery and functions. Seikagaku 70: 1315-1325, 1998 (in Japanese).
    OpenUrlPubMed
  17. ↵
    1. Mashour GA,
    2. Ratner N,
    3. Khan GA,
    4. Wang HL,
    5. Martuza RL,
    6. Kurtz A
    : The angiogenic factor midkine is aberrantly expressed in NF1-deficient Schwann cells and is a mitogen for neurofibroma-derived cells. Oncogene 20: 97-105, 2001.
    OpenUrlCrossRefPubMed
    1. Choudhuri R,
    2. Zhang HT,
    3. Donnini S,
    4. Ziche M,
    5. Bicknell R
    : An angiogenic role for the neurokines midkine and pleiotrophin in tumorigenesis. Cancer Res 57: 1814-1819, 1997.
    OpenUrlAbstract/FREE Full Text
    1. Qi M,
    2. Ikematsu S,
    3. Ichihara-Tanaka K,
    4. Sakuma S,
    5. Muramatsu T,
    6. Kadomatsu K
    : Midkine rescues Wilms' tumor cells from cisplatin-induced apoptosis: Regulation of Bcl-2 expression by midkine. J Biochem 127: 269-277, 2000.
    OpenUrlAbstract/FREE Full Text
    1. Kojima S,
    2. Inui T,
    3. Muramatsu H,
    4. Kimura T,
    5. Sakakibara S,
    6. Muramatsu T
    : Midkine is a heat and acid stable polypeptide capable of enhancing plasminogen activator activity and neurite outgrowth extension. Biochem Biophys Res Commun 216: 574-581, 1995.
    OpenUrlCrossRefPubMed
  18. ↵
    1. Kadomatsu K,
    2. Hagihara M,
    3. Akhter S,
    4. Fan QW,
    5. Muramatsu H,
    6. Muramatsu T
    : Midkine induces the transformation of NIH3T3 cells. Br J Cancer 75: 354-359, 1997.
    OpenUrlCrossRefPubMed
  19. ↵
    1. Tsutsui J,
    2. Kadomatsu K,
    3. Matsubara S,
    4. Nakagawara A,
    5. Hamanoue M,
    6. Takao S,
    7. Shimazu H,
    8. Ohi Y,
    9. Muramatsu T
    : A new family of heparin-binding growth/differentiation factors: increased midkine expression in Wilms' tumor and other human carcinomas. Cancer Res 53: 1281-1285, 1993.
    OpenUrlAbstract/FREE Full Text
    1. Aridome K,
    2. Tsutsui J,
    3. Takao S,
    4. Kadomatsu K,
    5. Ozawa M,
    6. Aikou T,
    7. Muramatsu T
    : Increased midkine gene expression in human gastrointestinal cancers. Jpn J Cancer Res 86: 655-661, 1995.
    OpenUrlCrossRef
    1. Garver RI Jr..,
    2. Radford DM,
    3. Donis-Keller H,
    4. Wick MR,
    5. Milner PG
    : Midkine and pleiotrophin expression in normal and malignant breast tissue. Cancer 74: 1584-1590, 1994.
    OpenUrlCrossRefPubMed
    1. Koide N,
    2. Hada H,
    3. Shinji T,
    4. Ujike K,
    5. Hirasaki S,
    6. Yumoto Y,
    7. Hanafusa T,
    8. Kadomatsu K,
    9. Muramatsu H,
    10. Muramatsu T,
    11. Tsuji T
    : Expression of the midkine gene in human hepatocellular carcinomas. Hepatogastroenterology 46: 3189-3196, 1999.
    OpenUrlPubMed
  20. ↵
    1. Muramatsu T
    : Midkine (MK), the product of a retinoic acid responsive gene, and pleiotrophin constitute a new protein family regulating growth and differentiation. Int J Dev Biol 37: 183-188, 1993.
    OpenUrlPubMed
PreviousNext
Back to top

In this issue

Anticancer Research: 32 (9)
Anticancer Research
Vol. 32, Issue 9
September 2012
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Gene Therapy Using Adenovirus Against Malignant Mesothelioma
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
8 + 11 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Gene Therapy Using Adenovirus Against Malignant Mesothelioma
AKINOBU GOTOH, TAKESHI KANNO, HISAO NAGAYA, TAKASHI NAKANO, CHIHARU TABATA, KAZUYA FUKUOKA, MASATOSHI TAGAWA, TOMOYUKI NISHIZAKI
Anticancer Research Sep 2012, 32 (9) 3743-3747;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Gene Therapy Using Adenovirus Against Malignant Mesothelioma
AKINOBU GOTOH, TAKESHI KANNO, HISAO NAGAYA, TAKASHI NAKANO, CHIHARU TABATA, KAZUYA FUKUOKA, MASATOSHI TAGAWA, TOMOYUKI NISHIZAKI
Anticancer Research Sep 2012, 32 (9) 3743-3747;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Conclusion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • 5-Azacytidine (5-aza) Induces p53-associated Cell Death Through Inhibition of DNA Methyltransferase Activity in Hep3B and HT-29 Cells
  • Prognostic Value of WNT1, NOTCH1, PDGFRβ, and CXCR4 in Oral Squamous Cell Carcinoma
  • Hypoxia-adapted Multiple Myeloma Stem Cells Resist γδ-T-Cell-mediated Killing by Modulating the Mevalonate Pathway
Show more Experimental Studies

Similar Articles

Anticancer Research

© 2023 Anticancer Research

Powered by HighWire